IDYA - Company ID 0001676725
The table below shows IDEAYA Biosciences, Inc.'s income statement by quarter, as reported in the company's quarterly filings. All figures are in US dollars; negative values appear in red.
| Line item | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q3 2024 |
|---|---|---|---|---|---|---|
| Revenue | $6.56M | - | $207.83M | - | - | $0.00 |
| Cost of revenue | - | - | - | - | - | - |
| Gross profit | - | - | - | - | - | - |
| R&D | $95.73M | $86.60M | $82.99M | $74.23M | $70.89M | $57.15M |
IDEAYA Biosciences, Inc. reported annual revenue of $218.71M for fiscal year 2025. That is up 3024.4% from $7.00M in fiscal 2024. Figures come from the company's audited annual reports as filed with the SEC.
Data parsed from SEC EDGAR XBRL filings. See the full market cap rankings.
| SG&A |
| $19.38M |
| - |
| $16.39M |
| $14.58M |
| $13.50M |
| $9.74M |
| Operating income | -$108.54M | - | $108.45M | -$88.81M | -$84.39M | -$66.89M |
| Income tax | $0.00 | - | - | $0.00 | $0.00 | $0.00 |
| Net income | -$98.54M | - | $119.24M | -$77.49M | -$72.18M | -$51.82M |
| EPS (diluted) | -$1.11 | - | $1.33 | -$0.88 | -$0.82 | -$0.60 |